The expression of PD-1 in TME was significantly reduced after applying DNA-PK inhibitors, and the combined application of anti-PD-1 antibodies further enhanced the immune system’s ability to attack tumor cells (Nakamura et al., 2021). This evidence concerns the gene PRKDC and neoplasm.